Syntara Limited specialises in the development of lysyl oxidase inhibitors, targeting fibrosis and inflammation. The company’s lead drug, SNT-5505, is in Phase 2 clinical trials for myelofibrosis and myelodysplastic syndrome, with promising interim results showing efficacy in reducing fibrosis. Syntara’s approach is rooted in pioneering research, including three publications in Nature, highlighting the potential of their therapies to transform treatment paradigms in fibrotic diseases. The company’s recent financial achievements include the strategic sale of its mannitol business, securing significant cost savings and long-term royalty income.
Syntara Limited (ASX:SNT)
A clinical-stage drug development company.
About Us
Syntara Limited is a biotechnology company leading the development of lysyl oxidase inhibitors with a focus on fibrosis and inflammation. The company has a robust pipeline of clinical-stage drugs addressing significant unmet needs in conditions such as myelofibrosis and myelodysplastic syndrome, backed by extensive research and strategic collaborations.
Company Overview
Board & Management
Kathleen Metters
Independent Chair
- Former Senior Vice President and Head of Worldwide Basic Research for Merck & Co. with oversight of all the company’s global research projects
- In a subsequent role at Merck &Co she led work on External Discovery and Preclinical Sciences
- Former CEO of biopharmaceutical company Lycera Corp
- Experienced senior global pharma executive with 30 years’ of experience in the biotechnology industry.
- Actively involved in CSL’s global expansion over a 17-year period where he held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL’s manufacturing plants in Germany and Australia.
- Prior to joining CSL he worked in the USA at leading biotechnology companies Genentech Inc and Chiron Corporation.
- 30+ years’ of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia
- Joined Pharmaxis in 2003 and was appointed Chief Executive Officer in March 2013 at which time he was Chief Operating Officer
- Previously held country and regional management roles at Novartis – Hungary, Asia Pacific and Australia
- Experienced life sciences investment professional with extensive knowledge of the biotech, pharmaceutical and medical technology sectors.
- Worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research.
- Prior to moving into life science investment Hashan worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.
